Platelet-Rich Plasma for Cardiac Conduction Abnormalities

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cardiac conduction abnormalities, such as arrhythmias, often have undesirable side effects, are invasive, or are not effective for a wide range of arrhythmias, necessitating the development of alternative methods for addressing these conditions.

Innovation Solution

The use of a platelet-rich plasma (PRP) composition, which may include buffering agents and anti-arrhythmic agents, is delivered to cardiac tissue to treat conduction abnormalities, either through injection or infusion, using minimally invasive procedures or open access methods, and can be prepared from the patient's own blood to minimize adverse reactions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional treatments (anti-arrhythmic agents, electrical pacing, radiofrequency ablation, cryo-cautery) are used to treat arrhythmias, then arrhythmia symptoms may be relieved, but undesirable side effects occur and the treatments are invasive

Engineering Contradiction:

Improvearrhythmia treatment effectivenessVSAvoidside effects and invasiveness

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses platelet-rich plasma (PRP) as an intermediary substance delivered via catheter to the cardiac conduction system. The PRP contains growth factors and cytokines that mediate the healing and regeneration of conduction tissue, providing a non-invasive alternative to traditional surgical or chemical treatments while maintaining effectiveness in treating arrhythmias

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces mechanical and chemical intervention systems (electrical pacing, radiofrequency ablation, cryo-cautery, anti-arrhythmic drugs) with a biological system using platelet-rich plasma. This substitution eliminates the harmful physical and chemical effects of traditional treatments while utilizing the body's own healing mechanisms through growth factors and cytokines present in PRP

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If traditional treatments are used to address specific arrhythmia types, then those specific conditions may be treated, but the treatments are not effective for a wide range of arrhythmias

Engineering Contradiction:

Improvetreatment applicability across arrhythmia typesVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent employs platelet-rich plasma as a universal treatment agent that can address multiple types of arrhythmias (atrial fibrillation, atrial flutter, ventricular tachycardia, bradycardia, heart block) through a single therapeutic mechanism. The PRP's growth factors and cytokines promote general conduction system health and regeneration, making the treatment adaptable to various arrhythmia etiologies without requiring different specialized interventions for each condition

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If invasive procedures (radiofrequency ablation, cryo-cautery, surgery) are performed to treat conduction abnormalities, then conduction pathways may be modified, but the procedures carry higher risks and require open access

Engineering Contradiction:

Improveconduction pathway modificationVSAvoidprocedure invasiveness

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces platelet-rich plasma as a mediatory substance delivered through a catheter system that requires only percutaneous access rather than open surgical procedures. The PRP acts as an intermediate carrier of growth factors and cytokines to the conduction system, achieving therapeutic effects without the need for invasive surgical intervention or complex implantable devices

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the fundamental parameter of treatment delivery from invasive surgical access to minimally invasive percutaneous catheter delivery. By transforming the administration route and using a biological fluid (PRP) instead of energy-based ablation or surgical manipulation, the procedure complexity and invasiveness are significantly reduced while maintaining therapeutic effectiveness

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS11638548B2Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities

Publication Date: 2023.05.02 BLUE ENGINE BIOLOGICS LLC

AI summary

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically.